ONCOTHERAPY SCIENCE, INC.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 2001-04-06
- Employees
- 54
- Market Cap
- -
- Website
- http://www.oncotherapy.co.jp
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
Phase 1
Terminated
- Conditions
- Relapsed or Refractory Synovial Sarcoma
- Interventions
- Drug: OTSA101-DTPA-111InDrug: OTSA101-DTPA-90Y
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04176016
- Locations
- π―π΅
Cancer Institute Hospital of JFCR, Tokyo, Japan
π―π΅National Cancer Center Hospital, Tokyo, Japan
π―π΅Osaka International Cancer Institute, Osaka, Japan
Safety Study of MELK Inhibitor to Treat Patients with Advanced Breast Cancer and Triple Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Relapsed/refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02926690
- Locations
- πΊπΈ
Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
πΊπΈNorwalk Hospital, Norwalk, Connecticut, United States
πΊπΈWeill Cornell Medicine | NewYork-Presbyterian, New York, New York, United States
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
Phase 1
Terminated
- Conditions
- AMLAdvanced MDSALLAdvanced CMLAdvanced MPNs
- Interventions
- Drug: OTS167IV
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02795520
- Locations
- πΊπΈ
Weill Cornell Medicine, New York, New York, United States
πΊπΈUniversity of Chicago, Chicago, Illinois, United States
Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: Cherry syrupDrug: OTS167IV
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02768519
- Locations
- π¦πΊ
CMAX, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Phase 1 Study of OTS167 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Metastatic TumorsSolid Tumors
- Interventions
- Drug: OTS167IV
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01910545
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
Β© Copyright 2025. All Rights Reserved by MedPath